How nanotechnology and biomedical engineering are supporting the identification of predictive biomarkers in neuro-oncology by Ganau, M, Paris, M, Syrmos, N, Ganau, L, Ligarotti, G, Moghaddamjou, A, Prisco, L, Ambu, R, Chibbaro, S

“…The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. …”

Brain white matter fibre tracts: a review of functional neuro-oncological relevance by Voets, N, Bartsch, A, Plaha, P

“…<p>State-of-the-art glioma treatment aims to maximise neuro-oncological benefit while minimising losses in quality of life. …”

Impact of COVID-19 pandemic on surgical neuro-oncology multi-disciplinary team decision making: A national survey (COVID-CNSMDT Study) by Price, SJ, Joannides, A, Plaha, P, Afshari, FT, Albanese, E, Barua, NU, Chan, HW, Critchley, G, Flannery, T, Fountain, DM, Mathew, RK, Piper, RJ, Poon, MT, Rajaraman, C, Rominiyi, O, Smith, S, Solomou, G, Solth, A, Surash, S, Wykes, V, Watts, C, Bulbeck, H, Hutchinson, P, Jenkinson, MD, COVID-CNSMDT study group

German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. by Herrlinger, U, Schabet, M, Brugger, W, Kortmann, R, Küker, W, Deckert, M, Engel, C, Schmeck-Lindenau, H, Mergenthaler, H, Krauseneck, P, Benöhr, C, Meisner, C, Wiestler, O, Dichgans, J, Kanz, L, Bamberg, M, Weller, M

“…The prospective multicenter NOA-03 trial, conducted by the Neuro-Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single-agent high-dose methotrexate therapy without concomitant radiotherapy in immunocompetent patients with primary central nervous system lymphoma. …”

The role of [18F]fluorodopa positron emission tomography in grading of gliomas by Roach, JR, Plaha, P, McGowan, DR, Higgins, GS

“…</p> <p><strong>Results:</strong>&nbsp;In 2016 the Response Assessment in Neuro-Oncology (RANO) and European Association for Neuro-Oncology (EANO) published recommendations on the clinical use of PET imaging in gliomas. …”

The influence of the α/β ratio on treatment time iso-effect relationships in the central nervous system by Jones, B, Klinge, T, Hopewell, JW

“…It is important to establish if an &#x3B1;/&#x3B2; ratio of 2&#x2009;Gy, the accepted norm for neuro-oncology iso-effect estimations, can be used.</p> <p><strong>Methods:</strong> The rat spinal cord irradiation data of Pop et&#xA0;al. provided ED50 values for radiation myelopathy for treatment times that varied from minutes to &#x223C;6&#x2009;days. …”

FUTURE-GB: functional and ultrasound-guided resection of glioblastoma – a two-stage randomised control trial by Plaha, P, Camp, S, Cook, J, McCulloch, P, Voets, N, Ma, R, Taphoorn, MJB, Dirven, L, Grech-Sollars, M, Watts, C, Bulbeck, H, Jenkinson, MD, Williams, M, Lim, A, Dixon, L, Price, SJ, Ashkan, K, Apostolopoulos, V, Barber, VS, Taylor, A, Nandi, D

“…There are multiple other surgical adjuncts available to the neuro-oncology surgeon. However, access to, and usage of these varies widely in UK practice, with limited evidence of their use. …”